A randomized study of high-dose cytarabine in induction in acute myeloid leukemia

Blood

Volumn 87, Issue 5, 1996, Pages 1710-1717

  Bishop, James F ^a,b   Matthews, Jane P ^a   Young, Graham A ^a   Szer, Jeffrey ^a   Gillett, Ann ^a   Joshua, Douglas ^a   Bradstock, Kenneth ^a   Enno, Arno ^a   Wolf, Max M ^a   Fox, Richard ^a   Cobcroft, Ralph ^a   Herrmann, Richard ^a   Van Der Weyden, Martin ^a   Lowenthal, Raymond M ^a   Page, Fiona ^a   Garson, O Margaret ^a   Juneja, Surender ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 9044228414     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.5.1710.bloodjournal8751710     Document Type: Article

References (30)

1. Yates J, Glidewell O, Wiernik PH, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurahi F, Green M, Henderson E, Leone L, Holland JF: Cytarabine with daunorubicin or adriamycin for therapy of acute myeloid leukemia: A CALGB study. Blood 60:2, 454, 1982
2. Priesler H, Davis RB, Kirshner J, Dupre E, Richards F, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre OR Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute non-lymphocytic leukemia. Blood 69:5, 1441, 1987
3. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Penman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:2, 313, 1992
4. Arlin Z, Case DC Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K: Randomised multicenter trial of Cytarabine with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177, 1990
5. Bishop JF: Etoposide in the treatment of leukemias. Semin Oncol 19:33, 1992 (suppl 13)
6. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W: Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia, an active and well tolerated regimen. J Clin Oncol 6:213, 1988
7. Hakami N, Look AT, Steuber PC, Krischer J, Castleberry R, Harris R, Ravindranath Y, Vietta TJ: Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia. J Clin Oncol 5:1022, 1987
8. Hiddemann W, Urbanitz D, Preusser P, Achterrath W, Buchner T: Treatment of refractory acute myeloid leukemia with M-AMSA and VP16-213 in combination: Hematol Oncol 7:267, 1989
9. Bishop JF, Joshua DE, Lowenthal RM, Kronenberg H, Whiteside MG, Cobcroft R, Dodds A, Wolf M, Manoharan H: A phase I-II study of Cytarabine, daunorubicin and VP16-213 in adult patients with acute non-lymphocytic leukemia Aust NZ J Med 16:48, 1986
10. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, Herrmann R, Szer J, Wolf MM, Young GA: Etoposide in acute non-lymphocytic leukemia. Blood 75:27, 1990
11. Elhson RR, Holland JF, Weil M, Jacquil-Lat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff N, Silver RT, Karana Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcier J, Moon JH: Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32:507, 1968
12. Plunkett W, Iacoboni S, Keating MJ: Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic blasts during treatment of refractory leukemia with high dose 1-β-D-arabinofuranosylcytosine. Scand J Haematol 44:51, 1986
13. Rustum YM, Preisler HD: Correlation between leukemic cell retention of 1-B-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39:42, 1979
14. Hines JD, Oken MM, Mazza J, Keller AM, Streeter RR, Glick JH et al: High dose Cytarabine and M-AMSA is effective therapy in relapsed acute non-lymphocytic leukemia. J Clin Oncol 2:2, 545, 1984 (suppl 1)
15. Champlin R, Ho W, Winston D, Decker R, Greenberg P, Burnison M, Holly FH, Gale RP: Treatment of adults with acute myelogenous leukemia: Prospective evaluation of high dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol 14:1, 1987
16. Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, Rai KR, Cornwell GG, Ellison RR, Maguire M, Berg DT, Davis RB, McIntyre OR, Frei E: Intensive post-remission therapy in adults with acute non-lymphocytic leukemia using various dose schedules of ara-C: A progress report from CALGB. Semin Oncol 14:2, 25, 1987 (suppl 1)
17. Brito-Babapulle F, Catovsky D, Newland AC, Goldman JM, Galton DAG: Treatment of acute myeloid leukemia with intermediate dose Cytarabine and mitoxantrone. Semin Oncol 14:2, 51, 1987 (suppl 1)
18. Bishop JF, Matthews JP, Young GA, Szer J, Joshua DE, Dodds A, Laidlaw CR, Cobcroft R, Herman R, Ma D, Page FJ: The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukaemia. Leuk Lymphoma 15:79, 1994
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620, 1985
20. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207, 1981
21. Kalbfleisch JD and Prentice RL: The Statistical Analyses of Failure Time Data. New York, NY, Wiley, 1980
22. Dixon WJ (ed): BMDP Statistical Software 1981. Berkeley, CA, University of California Press, 1981
23. Herzig RH, Herzig GP, Wolff SN, Hines JD, Fay JW, Phillips GL: Central nervous system effects of high-dose cytarabine. Semin Oncol 14:2, 21, 1987 (suppl 1)
24. Weick J, Kopecky J, Appelbaum F et al: A randomized investigation of high dose versus standard dose cytoside arabinoside with daunorubicin in patients with acute meylogenous leukemia. Proc Am Soc Clin Oncol 11:261, 1992 (abstr)
25. Plunkett W, Liliemark JO, Estey E, Keating MJ: Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:2, 159, 1987 (suppl 1)
26. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei IIIE: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
27. Gorin NC, Labopin M, Meloni G, Korbling M, Carella A, Herve P, Burnett A, Rizzoli V, Alessandrino EP, Bjorkstrand B, Ferrant A, Lowenberg B, Coser P, Simonsson B, Helbig W, Brunet Mauri S, Verdonck LF, Iriondo A, Polli E, Colombat P, Franklin IM, Souillet G, Willemze R: Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: Further evidence of the role of marrow purging by mafosfamide. Leukemia 5:896, 1991
28. Clift RA, Buchkner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M, et al: The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243, 1987
29. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edlestein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
30. Bishop JF: Intensified therapy for acute myeioid leukemia. N Engl J Med 331, 941, 1994